*EMBARGOED All research presented at the 2022 ACG Annual Scientific Meeting and Postgraduate Course is strictly embargoed until Sunday, October 23, 2022, at 12:00 pm EDT.
Tuesday, October 25, 2022 | 9:00 AM – 9:10 AM ET | Location: Hall C1
Author Insight from Anuragh Gudur, MD, University of Virginia
What’s new here and important for clinicians?
Endoscopic sleeve gastroplasty (ESG) and intragastric balloon (IGB) are the most commonly performed endoscopic bariatric therapies in the United States. It is important to analyze real-world practice data with respect to the clinical outcomes of these two procedures. These analyses will ultimately help guide our clinical discussions with patients regarding the risks, benefits, and expected outcomes for these elective procedures. Our large-scale retrospective analysis helps confirm some of the findings from the limited number of existing studies that directly compared ESG and IGB, notably that ESG appears to be more well-tolerated than IGB.
What do patients need to know?
Intragastric balloon placement is a temporary solution to weight loss, and patients are much more likely to experience clinically significant dehydration after the procedure compared to patients who undergo ESG. Patients who underwent intragastric balloon placement were more likely to require a repeat intervention compared to those who underwent ESG. Most of these repeat interventions were to remove the intragastric balloon early, due to side effects.
Read the Abstract
Anuragh Gudur, MD, University of Virginia
ycq3qt [at] virginia.edu
Media Interview Requests
To arrange an interview with any ACG experts or abstract authors, please contact Becky Abel of ACG via email at mediaonly [at] gi.org or by phone at 301-263-9000.